Literature DB >> 23238615

Epigenetic modifications in hepatic stellate cells contribute to liver fibrosis.

Qi Zhao1, Cheng-Yong Qin, Ze-Hua Zhao, Yu-Chen Fan, Kai Wang.   

Abstract

Liver fibrosis represents the final common pathway of virtually all types of chronic liver diseases, and it has been a major public health concern. Many genes have been demonstrated to be involved in the pathogenesis of liver fibrosis, while the mechanisms underlying gene regulation still needs further research. On the other hand, hepatic stellate cells (HSCs) are quiescent cells in the perisinusoidal space in liver. HSCs facilitate hepatocytes interactions via releasing soluble inflammatory factors and producing extracellular matrix. HSCs can be activated in response to liver injury, and they differentiate to myofibroblasts, which greatly contribute to the fibrogenesis process. Various epigenetic procedures, including DNA methylation, histone modification and formation of particular chromatin structure, play crucial roles in the gene transcriptional expression in HSCs, regulating various vital processes. For instance, epigenetic modulation on the peroxisome proliferator-activated receptor gamma (PPAR-γ) gene promoter accounts for HSC differentiation through interacting pathways. Aberrant expression of a series of histones and chemokines in activated HSCs can aggravate inflammation and oxidative stress, which in turn promotes differentiation of HSCs to myofibroblasts and enhances the whole fibrogenesis process. Degradation of extracellular matrix is also regulated through epigenetic modulation on matrix associated enzymes. Moreover, fibrosis-related epigenetic modifications in the parental generation may be inherited to their offspring. In this review, we firstly summarize the vital epigenetic modifications of fibrosis-related genes in HSCs, and highlight specific nucleic acid sequences and structures in gene promoters as important action sites, which may provide indicators for liver fibrosis diagnosis in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23238615     DOI: 10.1620/tjem.229.35

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  12 in total

Review 1.  Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico.

Authors:  Omar Ramos-Lopez; Erika Martinez-Lopez; Sonia Roman; Nora A Fierro; Arturo Panduro
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

2.  Epigenetic Changes during Hepatic Stellate Cell Activation.

Authors:  Silke Götze; Eva C Schumacher; Claus Kordes; Dieter Häussinger
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

Review 3.  Molecular mechanisms of liver fibrosis in HIV/HCV coinfection.

Authors:  Claudio M Mastroianni; Miriam Lichtner; Claudia Mascia; Paola Zuccalà; Vincenzo Vullo
Journal:  Int J Mol Sci       Date:  2014-05-26       Impact factor: 5.923

4.  MicroRNA-195 Activates Hepatic Stellate Cells In Vitro by Targeting Smad7.

Authors:  Li-Ying Song; Yu-Tao Ma; Cui-Fang Wu; Chun-Jiang Wang; Wei-Jin Fang; Shi-Kun Liu
Journal:  Biomed Res Int       Date:  2017-08-27       Impact factor: 3.411

5.  Long non-coding RNA PVT1 activates hepatic stellate cells through competitively binding microRNA-152.

Authors:  Jianjian Zheng; Fujun Yu; Peihong Dong; Limei Wu; Yuan Zhang; Yanwei Hu; Lei Zheng
Journal:  Oncotarget       Date:  2016-09-27

6.  Antioxidant axis Nrf2-keap1-ARE in inhibition of alcoholic liver fibrosis by IL-22.

Authors:  Ya-Hui Ni; Li-Juan Huo; Ting-Ting Li
Journal:  World J Gastroenterol       Date:  2017-03-21       Impact factor: 5.742

7.  The Active Components of Fuzheng Huayu Formula and Their Potential Mechanism of Action in Inhibiting the Hepatic Stellate Cells Viability - A Network Pharmacology and Transcriptomics Approach.

Authors:  Xinrui Xing; Si Chen; Ling Li; Yan Cao; Langdong Chen; Xiaobo Wang; Zhenyu Zhu
Journal:  Front Pharmacol       Date:  2018-05-24       Impact factor: 5.810

Review 8.  Elucidating Potential Profibrotic Mechanisms of Emerging Biomarkers for Early Prognosis of Hepatic Fibrosis.

Authors:  Mishghan Zehra; James C Curry; Sneha S Pillai; Hari Vishal Lakhani; Cory E Edwards; Komal Sodhi
Journal:  Int J Mol Sci       Date:  2020-07-03       Impact factor: 5.923

Review 9.  Co-infections as Modulators of Disease Outcome: Minor Players or Major Players?

Authors:  Priti Devi; Azka Khan; Partha Chattopadhyay; Priyanka Mehta; Shweta Sahni; Sachin Sharma; Rajesh Pandey
Journal:  Front Microbiol       Date:  2021-07-06       Impact factor: 5.640

10.  Expression and function of methylthioadenosine phosphorylase in chronic liver disease.

Authors:  Barbara Czech; Katja Dettmer; Daniela Valletta; Michael Saugspier; Andreas Koch; Axel P Stevens; Wolfgang E Thasler; Martina Müller; Peter J Oefner; Anja-Katrin Bosserhoff; Claus Hellerbrand
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.